Neoplastic Meningitis Due to Lung, Breast, and Melanoma Metastases. Le Rhun, E., Taillibert, S., & Chamberlain, M. C. Cancer Control, 24(1):22–32, January, 2017. ![Neoplastic Meningitis Due to Lung, Breast, and Melanoma Metastases [link]](https://bibbase.org/img/filetypes/link.svg "link")
Paper abstract bibtex BACKGROUND: Neoplastic meningitis, a central nervous system (CNS) complication of cancer metastatic to the meninges and cerebrospinal fluid (CSF), is relevant to oncologists due to the impact of the disease on patient quality of life and survival rates. METHODS: A review of the literature of articles published in English was conducted with regard to neoplastic meningitis. RESULTS: The incidence of neoplastic meningitis is increasing because patients with cancer are surviving longer in part because of the use of novel therapies with poor CNS penetration. Up to 5% of patients with solid tumors develop neoplastic meningitis during the disease course (breast cancer, lung cancer, and melanoma being the predominantly causative cancers). The rate of median survival in patients with untreated neoplastic meningitis is 1 to 2 months, although it can be as long as 5 months in some cases. Therapeutic options for the treatment of neoplastic meningitis include systemic therapy (cancer-specific, CNS-penetrating chemotherapy or targeted therapies), intra-CSF administration of chemotherapy (methotrexate, cytarabine, thiotepa) and CNS site-specific radiotherapy. Determining whom to treat with neoplastic meningitis remains challenging and, in part, relates to the extent of systemic disease, the neurological burden of disease, the available systemic therapies, and estimated rates of survival. CONCLUSIONS: The prognosis of neoplastic meningitis remains poor. The increasing use of novel, targeted therapies and immunotherapy in solid tumors and its impact on neoplastic meningitis remains to be determined and is an area of active research. Thus, well conducted trials are needed.
@article{le_rhun_neoplastic_2017,
title = {Neoplastic {Meningitis} {Due} to {Lung}, {Breast}, and {Melanoma} {Metastases}},
volume = {24},
issn = {1526-2359 (Electronic) 1073-2748 (Linking)},
url = {http://www.ncbi.nlm.nih.gov/pubmed/28178709},
abstract = {BACKGROUND: Neoplastic meningitis, a central nervous system (CNS) complication of cancer metastatic to the meninges and cerebrospinal fluid (CSF), is relevant to oncologists due to the impact of the disease on patient quality of life and survival rates. METHODS: A review of the literature of articles published in English was conducted with regard to neoplastic meningitis. RESULTS: The incidence of neoplastic meningitis is increasing because patients with cancer are surviving longer in part because of the use of novel therapies with poor CNS penetration. Up to 5\% of patients with solid tumors develop neoplastic meningitis during the disease course (breast cancer, lung cancer, and melanoma being the predominantly causative cancers). The rate of median survival in patients with untreated neoplastic meningitis is 1 to 2 months, although it can be as long as 5 months in some cases. Therapeutic options for the treatment of neoplastic meningitis include systemic therapy (cancer-specific, CNS-penetrating chemotherapy or targeted therapies), intra-CSF administration of chemotherapy (methotrexate, cytarabine, thiotepa) and CNS site-specific radiotherapy. Determining whom to treat with neoplastic meningitis remains challenging and, in part, relates to the extent of systemic disease, the neurological burden of disease, the available systemic therapies, and estimated rates of survival. CONCLUSIONS: The prognosis of neoplastic meningitis remains poor. The increasing use of novel, targeted therapies and immunotherapy in solid tumors and its impact on neoplastic meningitis remains to be determined and is an area of active research. Thus, well conducted trials are needed.},
number = {1},
journal = {Cancer Control},
author = {Le Rhun, E. and Taillibert, S. and Chamberlain, M. C.},
month = jan,
year = {2017},
keywords = {Breast Neoplasms/*complications/secondary, Combined Modality Therapy, Female, Humans, Lung Neoplasms/*complications/secondary, Melanoma/*complications/secondary, Meningitis/*etiology/therapy, Prognosis, Severity of Illness Index, Survival Rate},
pages = {22--32},
}
Downloads: 0
{"_id":"sooGCzSkNT4kHPCdh","bibbaseid":"lerhun-taillibert-chamberlain-neoplasticmeningitisduetolungbreastandmelanomametastases-2017","downloads":0,"creationDate":"2019-03-25T15:04:28.511Z","title":"Neoplastic Meningitis Due to Lung, Breast, and Melanoma Metastases","author_short":["Le Rhun, E.","Taillibert, S.","Chamberlain, M. C."],"year":2017,"bibtype":"article","biburl":"https://api.zotero.org/users/4915350/collections/YPPRWHHG/items?key=9UQuiwltMdY02lUFuEAB0dvL&format=bibtex&limit=100","bibdata":{"bibtype":"article","type":"article","title":"Neoplastic Meningitis Due to Lung, Breast, and Melanoma Metastases","volume":"24","issn":"1526-2359 (Electronic) 1073-2748 (Linking)","url":"http://www.ncbi.nlm.nih.gov/pubmed/28178709","abstract":"BACKGROUND: Neoplastic meningitis, a central nervous system (CNS) complication of cancer metastatic to the meninges and cerebrospinal fluid (CSF), is relevant to oncologists due to the impact of the disease on patient quality of life and survival rates. METHODS: A review of the literature of articles published in English was conducted with regard to neoplastic meningitis. RESULTS: The incidence of neoplastic meningitis is increasing because patients with cancer are surviving longer in part because of the use of novel therapies with poor CNS penetration. Up to 5% of patients with solid tumors develop neoplastic meningitis during the disease course (breast cancer, lung cancer, and melanoma being the predominantly causative cancers). The rate of median survival in patients with untreated neoplastic meningitis is 1 to 2 months, although it can be as long as 5 months in some cases. Therapeutic options for the treatment of neoplastic meningitis include systemic therapy (cancer-specific, CNS-penetrating chemotherapy or targeted therapies), intra-CSF administration of chemotherapy (methotrexate, cytarabine, thiotepa) and CNS site-specific radiotherapy. Determining whom to treat with neoplastic meningitis remains challenging and, in part, relates to the extent of systemic disease, the neurological burden of disease, the available systemic therapies, and estimated rates of survival. CONCLUSIONS: The prognosis of neoplastic meningitis remains poor. The increasing use of novel, targeted therapies and immunotherapy in solid tumors and its impact on neoplastic meningitis remains to be determined and is an area of active research. Thus, well conducted trials are needed.","number":"1","journal":"Cancer Control","author":[{"propositions":[],"lastnames":["Le","Rhun"],"firstnames":["E."],"suffixes":[]},{"propositions":[],"lastnames":["Taillibert"],"firstnames":["S."],"suffixes":[]},{"propositions":[],"lastnames":["Chamberlain"],"firstnames":["M.","C."],"suffixes":[]}],"month":"January","year":"2017","keywords":"Breast Neoplasms/*complications/secondary, Combined Modality Therapy, Female, Humans, Lung Neoplasms/*complications/secondary, Melanoma/*complications/secondary, Meningitis/*etiology/therapy, Prognosis, Severity of Illness Index, Survival Rate","pages":"22–32","bibtex":"@article{le_rhun_neoplastic_2017,\n\ttitle = {Neoplastic {Meningitis} {Due} to {Lung}, {Breast}, and {Melanoma} {Metastases}},\n\tvolume = {24},\n\tissn = {1526-2359 (Electronic) 1073-2748 (Linking)},\n\turl = {http://www.ncbi.nlm.nih.gov/pubmed/28178709},\n\tabstract = {BACKGROUND: Neoplastic meningitis, a central nervous system (CNS) complication of cancer metastatic to the meninges and cerebrospinal fluid (CSF), is relevant to oncologists due to the impact of the disease on patient quality of life and survival rates. METHODS: A review of the literature of articles published in English was conducted with regard to neoplastic meningitis. RESULTS: The incidence of neoplastic meningitis is increasing because patients with cancer are surviving longer in part because of the use of novel therapies with poor CNS penetration. Up to 5\\% of patients with solid tumors develop neoplastic meningitis during the disease course (breast cancer, lung cancer, and melanoma being the predominantly causative cancers). The rate of median survival in patients with untreated neoplastic meningitis is 1 to 2 months, although it can be as long as 5 months in some cases. Therapeutic options for the treatment of neoplastic meningitis include systemic therapy (cancer-specific, CNS-penetrating chemotherapy or targeted therapies), intra-CSF administration of chemotherapy (methotrexate, cytarabine, thiotepa) and CNS site-specific radiotherapy. Determining whom to treat with neoplastic meningitis remains challenging and, in part, relates to the extent of systemic disease, the neurological burden of disease, the available systemic therapies, and estimated rates of survival. CONCLUSIONS: The prognosis of neoplastic meningitis remains poor. The increasing use of novel, targeted therapies and immunotherapy in solid tumors and its impact on neoplastic meningitis remains to be determined and is an area of active research. Thus, well conducted trials are needed.},\n\tnumber = {1},\n\tjournal = {Cancer Control},\n\tauthor = {Le Rhun, E. and Taillibert, S. and Chamberlain, M. C.},\n\tmonth = jan,\n\tyear = {2017},\n\tkeywords = {Breast Neoplasms/*complications/secondary, Combined Modality Therapy, Female, Humans, Lung Neoplasms/*complications/secondary, Melanoma/*complications/secondary, Meningitis/*etiology/therapy, Prognosis, Severity of Illness Index, Survival Rate},\n\tpages = {22--32},\n}\n\n","author_short":["Le Rhun, E.","Taillibert, S.","Chamberlain, M. C."],"key":"le_rhun_neoplastic_2017","id":"le_rhun_neoplastic_2017","bibbaseid":"lerhun-taillibert-chamberlain-neoplasticmeningitisduetolungbreastandmelanomametastases-2017","role":"author","urls":{"Paper":"http://www.ncbi.nlm.nih.gov/pubmed/28178709"},"keyword":["Breast Neoplasms/*complications/secondary","Combined Modality Therapy","Female","Humans","Lung Neoplasms/*complications/secondary","Melanoma/*complications/secondary","Meningitis/*etiology/therapy","Prognosis","Severity of Illness Index","Survival Rate"],"downloads":0},"search_terms":["neoplastic","meningitis","due","lung","breast","melanoma","metastases","le rhun","taillibert","chamberlain"],"keywords":["female","humans","prognosis","survival rate","breast neoplasms/*complications/secondary","combined modality therapy","lung neoplasms/*complications/secondary","melanoma/*complications/secondary","meningitis/*etiology/therapy","severity of illness index"],"authorIDs":[],"dataSources":["nujP43M5eTb6b6trn"]}